LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference
18 May 2021 - 8:30PM
LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company
focused on applying its expertise in bispecific gamma-delta T cell
engagers to transform cancer therapy, today announced that Stephen
Hurly, chief executive officer, will present at the 2021 UBS Global
Healthcare Virtual Conference on Wednesday, May 26, 2021 at 1:00
p.m. ET.
The presentation will be webcast and can be accessed from the
investor relations section of the company's website at
www.lavatherapeutics.com.
About LAVA
LAVA Therapeutics N.V. is a clinical stage biotechnology company
developing a portfolio of bispecific gamma-delta T cell engagers
(gamma-delta bsTCEs) for the treatment of solid tumors and
hematological malignancies based on its proprietary platform. The
company’s innovative approach utilizes bispecific antibodies
engineered to selectively kill cancer cells and induce gamma-delta
T cell-mediated immunity through activation of Vγ9Vδ2 T cells upon
cross-linking to tumor associated antigens. A Phase 1/2a clinical
study evaluating LAVA-051 in patients with certain hematologic
malignancies is anticipated to generate top line clinical data in
the first half of 2022. The Company expects to initiate a Phase
1/2a clinical study to evaluate LAVA-1207 in patients with prostate
cancer in the second half of 2021. For more information, please
visit www.lavatherapeutics.com.
ContactChelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2023 to Apr 2024